Literature DB >> 20105568

Hemihyperplasia-multiple lipomatosis syndrome: an underdiagnosed entity in children with asymmetric overgrowth.

Ozlem Boybeyi1, Yasemin Alanay, Aycan Kayikçioğlu, Ibrahim Karnak.   

Abstract

Hemihyperplasia can be found as an isolated abnormality, or as a predominant associated feature of an asymmetric overgrowth syndrome. This report describes 2 patients with hemihyperplasia-multiple lipomatosis syndrome. The finding of hemihyperplasia prompts careful examination for associated lipomatous lesions. Close follow-up is required because progressive growth of lipomatous lesions can be encountered as well as recurrence after excision. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20105568     DOI: 10.1016/j.jpedsurg.2009.10.059

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  4 in total

1.  Unusual thymic hyperplasia mimicking lipomatous tumor in an eight-year-old boy with concomitant pericardial lipomatosis and right facial hemihypertrophy.

Authors:  Yoo Jin Kim; Woo Sun Kim; Jung-Eun Cheon; Yun-Jung Lim; In-One Kim; Kyung Mo Yeon; Kyeong Cheon Jung; Sun-Ju Byun
Journal:  Korean J Radiol       Date:  2011-04-25       Impact factor: 3.500

Review 2.  Imaging appearances of soft-tissue tumors of the pediatric foot: review of a 15-year experience at a tertiary pediatric hospital.

Authors:  Pablo Caro-Domínguez; Oscar M Navarro
Journal:  Pediatr Radiol       Date:  2017-10-26

3.  Idiopathic hemihypertrophy with multiple fibroadenoma.

Authors:  Asha Nyati; Sarita Kalwaniya; Parul Agarwal
Journal:  Indian Dermatol Online J       Date:  2016 Jul-Aug

4.  Complex vascular anomalies and tissue overgrowth of limbs associated with increased skin temperature and peripheral venous dilatation: parks weber syndrome or PROS?

Authors:  Li Xin Su; Yi Sun; Xindong Fan; Ren Cai; Zhenfeng Wang; Deming Wang; Xitao Yang; Lianzhou Zheng; Mingzhe Wen
Journal:  Hereditas       Date:  2022-01-04       Impact factor: 3.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.